- Home
- RLTY vs FHTX Comparison
RLTY vs FHTX Comparison
Compare RLTY & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- FHTX
- Stock Information
- Founded
- RLTY 2022
- FHTX 2015
- Country
- RLTY United States
- FHTX United States
- Employees
- RLTY N/A
- FHTX N/A
- Industry
- RLTY Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- RLTY Finance
- FHTX Health Care
- Exchange
- RLTY Nasdaq
- FHTX Nasdaq
- Market Cap
- RLTY 250.8M
- FHTX 246.6M
- IPO Year
- RLTY N/A
- FHTX 2020
- Fundamental
- Price
- RLTY $14.96
- FHTX $4.68
- Analyst Decision
- RLTY
- FHTX Strong Buy
- Analyst Count
- RLTY 0
- FHTX 6
- Target Price
- RLTY N/A
- FHTX $11.83
- AVG Volume (30 Days)
- RLTY 86.7K
- FHTX 268.1K
- Earning Date
- RLTY 01-01-0001
- FHTX 11-05-2025
- Dividend Yield
- RLTY 9.35%
- FHTX N/A
- EPS Growth
- RLTY N/A
- FHTX N/A
- EPS
- RLTY N/A
- FHTX N/A
- Revenue
- RLTY N/A
- FHTX $24,518,000.00
- Revenue This Year
- RLTY N/A
- FHTX $42.43
- Revenue Next Year
- RLTY N/A
- FHTX $14.77
- P/E Ratio
- RLTY N/A
- FHTX N/A
- Revenue Growth
- RLTY N/A
- FHTX N/A
- 52 Week Low
- RLTY $11.38
- FHTX $2.95
- 52 Week High
- RLTY $14.60
- FHTX $8.98
- Technical
- Relative Strength Index (RSI)
- RLTY 45.81
- FHTX 57.13
- Support Level
- RLTY $14.94
- FHTX $4.33
- Resistance Level
- RLTY $15.39
- FHTX $4.60
- Average True Range (ATR)
- RLTY 0.19
- FHTX 0.37
- MACD
- RLTY 0.01
- FHTX 0.08
- Stochastic Oscillator
- RLTY 37.10
- FHTX 95.95
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.